Axonics Modulation Technologies, which is commercializing a neural implant for overactive bladder and incontinence, raised $120 million by offering 8 million shares at $15, the midpoint of the $14 to $16 range. Axonics previously filed to offer 6.7 million shares at the same range. Axonics Modulation Technologies plans to list on the Nasdaq under the symbol AXNX. BofA Merrill Lynch and Morgan Stanley acted as lead managers on the deal.
